Stockscreener 앱 받기
59.38
2.75%
-1.76
전일 마감가:
$61.14
열려 있는:
$60.45
하루 거래량:
3.73M
Relative Volume:
0.81
시가총액:
$22.90B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
25.40
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
-1.49%
1개월 성능:
-5.80%
6개월 성능:
-0.44%
1년 성능:
-29.31%
1일 변동 폭
$58.64
$61.35
1주일 범위
$58.42
$61.55
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
59.35 | 23.59B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
83.78 | 146.92B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.99 | 112.88B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.24 | 98.63B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.66 | 80.41B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.09 | 45.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Dexcom stock (US2521311074): Q1 2026 earnings beat with 15% revenue growth - AD HOC NEWS
Is DexCom (DXCM) Share Weakness Creating A Valuation Opportunity For Investors? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom stock (US2521311074): Benchmark starts coverage with buy on G7 launch - AD HOC NEWS
Sell in May and Go Away—Starting With These 3 Stocks - Investing.com
DexCom stock price target maintained at $75 by TD Cowen ahead of investor day By Investing.com - Investing.com
Devon Energy stock (US2521311074): Q1 2026 earnings miss revenue, stock drops 9% - AD HOC NEWS
Dexcom gets a new Buy rating at Benchmark on expected margin expansion - Investing.com Canada
Benchmark initiates DexCom stock coverage with buy on G7 launch - Investing.com
Sava Appoints Former Dexcom EMEA Executive as Chief Commercial Officer - Fintech Finance
Benchmark Initiates DexCom at Buy With $77 Price Target - marketscreener.com
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom stock (US2521311074): Q1 2026 earnings beat estimates with $0.56 EPS - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Analysis: 37.83% Potential Upside Captivates Investors - DirectorsTalk Interviews
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - MSN
Dexcom Inc. stock (US2521311074): Investor Day in focus as growth outlook draws scrutiny - AD HOC NEWS
FinancialContentDexCom, Inc.Common Stock (Nasdaq:DXCM) Stock Quote - FinancialContent
How Investors May Respond To DexCom (DXCM) Strong Q1 2026 Earnings And Reaffirmed Revenue Outlook - Sahm
BTIG Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Dexcom Inc. stock (US2521311074): Q1 earnings beat lifts shares near $61 on Nasdaq - AD HOC NEWS
Alphabet reports stake in PayPay and CME Group, dissolves in Dexcom - marketscreener.com
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom's (NASDAQ:DXCM) Strong Earnings Are Of Good Quality - Yahoo Finance
5 Insightful Analyst Questions From DexCom’s Q1 Earnings Call - Barchart.com
DexCom (DXCM) Reports Q1 2026 Revenue of $1.19B with 15% Growth - Insider Monkey
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - TMX Newsfile
DexCom (DXCM) Q1 2026 Earnings Transcript - AOL.com
DexCom : Trade Association Report 2025 - marketscreener.com
Argus Adjusts Price Target on DexCom to $86 From $90 - marketscreener.com
Dexcom to Host Investor Day on May 14, 2026 - BioSpace
Alert from law firm tagged to Dexcom withdrawn - marketscreener.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
3 reasons analysts love DexCom - MSN
3 Reasons Analysts Love DexCom - MarketBeat
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
JPMorgan prices $345K DexCom‑linked callable notes | JPM Prospectus Summary - Stock Titan
PFA Pension Forsikringsaktieselskab Acquires New Stake in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. (DXCM) Stock Analysis: Unveiling a 36% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Should DexCom’s Margin Gains and Expanded Coverage Require Action From DexCom (DXCM) Investors? - Yahoo Finance
Canaccord Genuity Adjusts Price Target on DexCom to $100 From $95, Maintains Buy Rating - Moomoo
Dexcom, Inc. Q1 2026 Financial Results: Strong Revenue, Earnings, and Forward-Looking Statements - Minichart
Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom, Inc. - Moomoo
DexCom Faces Potential Headwinds in 2026, but Expanding Reimbursement Offers Long-Term Prospects - Morningstar
DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says - marketscreener.com
JPMorgan Adjusts DexCom Price Target to $65 From $75 - marketscreener.com
DexCom, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:DXCM) 2026-05-01 - Seeking Alpha
DexCom, Inc. (NASDAQ:DXCM) Q1 2026 Earnings Call Transcript - Insider Monkey
DexCom, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook - Yahoo Finance
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals - ChartMill
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
덱스컴 주식 (DXCM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Brown Michael Jon | EVP, Chief Legal Officer |
Apr 15 '26 |
Sale |
63.04 |
1,700 |
107,168 |
111,204 |
5.85%
4.23%
자본화:
|
볼륨(24시간):